Skip to content

Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01623934
Acronym
GEN3G
Enrollment
1034
Registered
2012-06-20
Start date
2010-01-31
Completion date
2025-09-30
Last updated
2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Insulin Resistance, Obesity Prevention

Keywords

Gestational diabetes, Adiponectin, Leptin, Single Nucleotides Polymorphisms, Insulin resistance, obesity

Brief summary

This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3, 5 and 10-12 year after delivery. The purpose of this phase 1 is to : * assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes; * assess levels of maternal adipokines as determinants of development and fetal growth; * determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns. The purpose of this phase 2 is to: * identify DNA methylation variations at birth that are predictive of childhood overweight/obesity. * identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity. * establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age). * identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3, 5 and 10 years of age.

Interventions

None listed

Sponsors

Fonds de la Recherche en Santé du Québec
CollaboratorOTHER_GOV
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
American Diabetes Association
CollaboratorOTHER
Diabetes Québec
CollaboratorOTHER
Université de Sherbrooke
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18 yrs * gestational age between 6 and 13 weeks from last menstrual period * no recognized diabetes or drugs interfering with glucose metabolism * alcohol \< 2 drinks/day * not involved in regular high intensity physical activity * otherwise good health status

Exclusion criteria

* twin pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of gestational diabetes mellitus24-28 weeks of gestation75g oral glucose tolerance test

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026